THE DOSE
your daily dose of Innovative, trending, and groundbreaking stories from across the cosmos.
Atai Life Gets FDA Approval to Study Ketamine Therapy
The U.S. Food and Drug Administration has authorized The Peter Thiel-Backed Psychedelics Company German psychedelics startup Atai Life Sciences to conduct a clinical trial on a nonpsychedelic form of ketamine for treatment-resistant depression.
